Dr Kaitin writes and speaks frequently on factors that contribute to the slow pace and high cost of pharmaceutical R&amp,D and the impact of efforts to speed the drug development process.

Konstanz biologist Patrick Müller receives a Proof of Concept Grant from the European Research Council for his project "EmbryoNet-AI". Its goal is the further development of an AI-supported platform ...

APAC offers stability in an increasing challenging global geopolitical environment for clinical stage drug development.

With continued investment and growing buzz from the industry, the AI hype is expected to extend through 2025 and beyond.

The pharmaceutical industry is on the verge of a significant transformation due to the emergence of artificial intelligence ...

In the face of such pressure, pharmaceutical companies are ... to eliminate costly inefficiencies in the drug discovery and development process. The high risk/reward ratio for drug development ...

“So, we need to increase efficiency on the process development side. While automation is one way of doing that, a much more efficient solution is to use in silico process development data to increase ...

The IRA’s price controls discourage post-marketing research. The potential benefits from expanding access to the drug to ...

The field of drug discovery faces many time-honored challenges. These include high costs, long development times and high rates of failure. The rise of artificial intelligence (AI) technology has been ...

"And we're not used to having somebody without a career at stake in the room at a senior level," said Hudson.

a degree in the pharmaceutical sciences may be for you. Our undergraduate program focuses on the design, development and rational use of medication for the prevention and treatment of disease, as well ...